ScholarIQanswers from OpenAlex & ORCID
Kiyotaka Yoh
ResearcherPublications, citations & collaboration network
Kiyotaka Yoh is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Kiyotaka Yoh have?
ScholarIQindexed works
Kiyotaka Yoh has 490 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Kiyotaka Yoh have?
ScholarIQcitation count
Kiyotaka Yoh has 9,550 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Kiyotaka Yoh?
ScholarIQh-index
Kiyotaka Yoh has an h-index of 46 in OpenAlex.
What is the i10-index of Kiyotaka Yoh?
ScholarIQi10-index
Kiyotaka Yoh has an i10-index of 136 in OpenAlex.
What is the ORCID of Kiyotaka Yoh?
ScholarIQorcid
The ORCID for Kiyotaka Yoh is on the source record.
What is the OpenAlex record for Kiyotaka Yoh?
ScholarIQopenalex
The OpenAlex for Kiyotaka Yoh is on the source record.
What are the most-cited papers on Kiyotaka Yoh?
ScholarIQmost cited works
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto, Makoto Nishio, Santiago Ponce Aix, Luis Paz‐Ares, Chao‐Hua Chiu, Keunchil Park, Silvia Novello, Ernest Nadal, Fumio Imamura, Kiyotaka Yoh, Jin‐Yuan Shih, Kwok Hung Au, Denis Moro‐Sibilot, Sotaro Enatsu, Annamaria H. Zimmermann, Bente Frimodt‐Moller, Carla Visseren‐Grul, Martin Reck, Quincy S. Chu, Alexis B. Cortot, Jean-Louis Pujol, Denis Moro‐Sibilot, Elizabeth Fabre, Corinne Lamour, Helge Bischoff, Jens Kollmeier, Martin Reck, Martin Kimmich, Walburga Engel-Riedel, Stefan Hammerschmidt, Wolfgang Schütte, Konstantinos Syrigos, Jcm Ho, Kwok‐Hung Au, Silvia Novello, Andrea Ardizzoni, Giulia Pasello, Vanessa Gregorc, Alessandro Del Conte, Domenico Galetta, Toshiaki Takahashi, Kazuhiko Nakagawa, Makoto Nishio, Kiyotaka Yoh, Takashi Seto, Fumio Imamura, Toru Kumagai, Katsuyuki Hotta, Yasushi Goto, Yukio Hosomi, Hiroshi Sakai, Yuichi Takiguchi, Young Hak Kim, Takayasu Kurata, Hiroyuki Yamaguchi, Haruko Daga, Isamu Okamoto, Miyako Satouchi, Satoshi Ikeda, Kazuo Kasahara, Shinji Atagi, Koichi Azuma, Toru Kumagai, Keisuke Aoe, Toru Kumagai, Keisuke Aoe, Yoshitsugu Horio, Nobuyuki Yamamoto, Hiroshi Tanaka, Satoshi Watanabe, Naoyuki Nogami, Tomohiro Ozaki, Ryo Koyama, Tomonori Hirashima, Hiroyasu Kaneda, Keisuke Tomii, Yuka Fujita, Masahiro Seike, Naoki Nishimura, Terufumi Kato, Masao Ichiki, Hideo Saka, Katsuya Hirano, Yasuharu Nakahara, Shunichi Sugawara, Keunchil Park, Sang‐We Kim, Young Joo Min, Hyun Woo Lee, Jin‐Hyoung Kang, Ho Jung An, Ki Hyeong Lee, Jin-Soo Kim, Gyeong‐Won Lee, Sung Yong Lee, Aurelia Alexandru, Anghel Adrian Udrea, Óscar Juan
Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component
James Chih‐Hsin Yang, Myung‐Ju Ahn, Dong‐Wan Kim, Suresh S. Ramalingam, Lecia V. Sequist, Wu‐Chou Su, Sang-We Kim, Joo-Hang Kim, David Planchard, Enriqueta Felip, Fiona Blackhall, Daniel Haggstrom, Kiyotaka Yoh, Silvia Novello, Kathryn A. Gold, Tomonori Hirashima, Chia‐Chi Lin, Helen Mann, Mireille Cantarini, Serban Ghiorghiu, Pasi A. Jänne
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
Jean‐Charles Soria, Yi‐Long Wu, Kazuhiko Nakagawa, Sang-We Kim, Jin-Ji Yang, Myung‐Ju Ahn, Jie Wang, James Chih‐Hsin Yang, You Lü, Shinji Atagi, Santiago Ponce, Ki Hyeong Lee, Yunpeng Liu, Kiyotaka Yoh, Jianying Zhou, Xiaojin Shi, Alan Webster, Haiyi Jiang, Tony Mok
Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial
Kiyotaka Yoh, Takashi Seto, Miyako Satouchi, Makoto Nishio, Noboru Yamamoto, Haruyasu Murakami, Naoyuki Nogami, Shingo Matsumoto, Takashi Kohno, Koji Tsuta, Katsuya Tsuchihara, Genichiro Ishii, Shogo Nomura, Akihiro Sato, Atsushi Ohtsu, Yuichiro Ohe, Kōichi Goto
Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer.
Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Kōichi Goto